# NeoTrio (NCT02858921)

> Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma

No report yet. It can be ordered.

- Indication: BRAF V600-mutant resectable stage III melanoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02858921
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Melanoma Institute Australia
- Conditions: Melanoma
- Interventions: Dabrafenib; Trametinib; Pembrolizumab
- Enrollment: 60
- Primary outcome: Pathological Response Rate

## Indexed commentary on NeoTrio so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 6 posts on X
- 1 YouTube video
- 1 podcast episode

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=neotrio-nct02858921

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02858921", "email": "<work email>"}; the inbox owner confirms by the emailed link.